The amount of cash inflow from collaborative agreement that was received as an upfront payment upon closing.

No definition available.

Name:	ptct_CashProceedsCollaborativeAgreementUpfrontPayment
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of development milestone obligation revenue received during the period.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestoneObligationRevenueReceived
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage reduction in disease progression observed in treated participants compared with a specified comparator population.

+ References

No definition available.

+ Details

Name:	ptct_DiseaseProgressionSlowingPercentage
Namespace Prefix:	ptct_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the age of participants eligible for enrollment in a clinical trial.

+ References

No definition available.

+ Details

Name:	ptct_EligibleAgeClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period, covered by participant data included in an interim analysis of a clinical trial.

+ References

No definition available.

+ Details

Name:	ptct_InterimAnalysisPeriodClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of individuals expected to enroll in clinical trial.

+ References

No definition available.

+ Details

Name:	ptct_NumberOfIndividualsExpectedToEnrollInClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of products of the company.

+ References

No definition available.

+ Details

Name:	ptct_NumberOfProducts
Namespace Prefix:	ptct_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Ratio used to randomize participants between treatment and control groups in a clinical trial.

+ References

No definition available.

+ Details

Name:	ptct_RandomizationRatioClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period over which a clinical trial or study is conducted.

+ References

No definition available.

+ Details

Name:	ptct_StudyDurationClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Period of votoplam treatment evaluated in comparison with an external natural history cohort.

+ References

No definition available.

+ Details

Name:	ptct_TreatmentComparisonPeriodClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of investigational product administered to participants in a clinical trial.

+ References

No definition available.

+ Details

Name:	ptct_TreatmentDosageClinicalTrial
Namespace Prefix:	ptct_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_StatementScenarioAxis=ptct_ProveFaStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptct_NovartisPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptct_LicenseAndCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptct_Phase3VotoplamTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company (Details) $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
The Company (Details) $ in Thousands	Apr. 30, 2026 USD ($) item age	Jan. 31, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2026 USD ($) product	Dec. 31, 2025 USD ($)
Collaboration and royalty revenue
Number of products \| product				2
Accumulated deficit			$ (2,883,542)	$ (2,883,542)	$ (2,964,229)
PROVE-FA
Collaboration and royalty revenue
Number of individuals expected to enroll \| item	120
Study duration, clinical trial	84 days
PROVE-FA \| Minimum
Collaboration and royalty revenue
Eligible age, clinical trial \| age	7
PROVE-FA \| Maximum
Collaboration and royalty revenue
Eligible age, clinical trial \| age	21
Novartis
Collaboration and royalty revenue
Development milestone obligation revenue received				50,000
License and Collaboration Agreement \| Novartis
Collaboration and royalty revenue
Cash proceeds from upfront payment on collaboration agreement		$ 1,000,000
License and Collaboration Agreement \| Novartis \| Phase 3 Votoplam trial
Collaboration and royalty revenue
Number of individuals expected to enroll \| item	770
Randomization ratio, clinical trial	1.5
Treatment dosage, clinical trial (milligrams) \| item	10
Development milestone obligation revenue received	$ 50,000		$ 50,000	$ 50,000
Interim analysis period, clinical trial	24 months
Treatment comparison period, clinical trial	24 months
Disease progression slowing percentage	52